Diclofenac hydroxylation in monkeys: Efficiency, regioselectivity, and response to inhibitors

Biochemical Pharmacology

Volumn 73, Issue 6, 2007, Pages 880-890

  Tang, Cuyue ^a   Fang, Yulin ^a   Booth Genthe, Catherine ^a   Kuo, Yuhsin ^a   Kuduk, Scott D ^a   Rushmore, Tom H ^a   Carr, Brian A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Catalytic efficiency; Diclofenac hydroxylation; Monkey liver microsomes; Recombinant monkey CYP2C and CYP3A; Regioselectivity and response to chemical inhibitors

Indexed keywords

CYTOCHROME P450 2C; CYTOCHROME P450 3A; DICLOFENAC; ENZYME INHIBITOR; KETOCONAZOLE; MONOCLONAL ANTIBODY; N (2 HYDROXY 1 INDANYL) 5 [2 [[(1,1 DIMETHYLETHYL)AMINO]CARBONYL] 4 [(FURO[2,3 B]PYRIDIN 5 YL)METHYL]PIPERAZIN 1 YL] 4 HYDROXY 2 (PHENYLMETHYL)PENTANAMIDE; OXYGENASE; RECOMBINANT ENZYME; SULFAPHENAZOLE; TIENILIC ACID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CATALYSIS; CHEMICAL STRUCTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG HYDROXYLATION; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME KINETICS; FEMALE; GENE EXPRESSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; LIVER MICROSOME; MALE; MONKEY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; CATALYSIS; CERCOPITHECUS AETHIOPS; CYTOCHROME P-450 ENZYME SYSTEM; DICLOFENAC; ENZYME INHIBITORS; FEMALE; HUMANS; HYDROXYLATION; KINETICS; MACACA FASCICULARIS; MACACA MULATTA; MALE; MICROSOMES, LIVER;

EID: 33846884645     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2006.11.016     Document Type: Article

References (43)

1. Rendic S., and Di Carlo F.J. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev 29 (1997) 413-580
2. Miners J.O., and Birkett D.J. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 45 (1998) 525-538
3. Goldstein JA. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 52 (2001) 349-355
4. Tucker G.T., Houston J.B., and Huang S.M. Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential-toward a consensus. Pharm Res 18 (2001) 1071-1080
5. Mancy A., Antignac M., Minoletti C., Dijols S., Mouries V., Duong N.T., et al. Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry 38 (1999) 14264-14270
6. Payne V.A., Chang Y.T., and Loew G.H. Homology modeling and substrate binding study of human CYP2C9 enzyme. Proteins 37 (1999) 176-190
7. Melet A., Assrir N., Jean P., Pilar Lopez-Garcia M., Marques-Soares C., Jaouen M., et al. Substrate selectivity of human cytochrome P450 2C9: importance of residues 476,365 and 114 in recognition of diclofenac and sulfaphenazole and in mechanism-based inactivation by tienilic acid. Arch Biochem Biophys 409 (2003) 80-91
8. Tang C., Kassahun K., McIntosh I.S., Brunner J., and Rodrigues A.D. Simultaneous determination of urinary free cortisol and 6beta-hydroxycortisol by liquid chromatography-atmospheric pressure chemical ionization tandem mass spectrometry and its application for estimating hepatic CYP3A induction. J Chromatogr B Biomed Sci Appl 742 (2000) 303-313
9. Jin L., Chen I.W., Chiba M., and Lin J.H. Interaction with indinavir to enhance systemic exposure of an investigational HIV protease inhibitor in rats, dogs and monkeys. Xenobiotica 33 (2003) 643-654
10. Kumar S., Kwei G.Y., Poon G.K., Iliff S.A., Wang Y., Chen Q., et al. Pharmacokinetics and interactions of a novel antagonist of chemokine receptor 5 (CCR5) with ritonavir in rats and monkeys: role of CYP3A and P-glycoprotein. J Pharmacol Exp Ther 304 (2003) 1161-1171
11. Kanazu T., Yamaguchi Y., Okamura N., Baba T., and Koike M. Model for the drug-drug interaction responsible for CYP3A enzyme inhibition. I: evaluation of cynomolgus monkeys as surrogates for humans. Xenobiotica 34 (2004) 391-402
12. Prueksaritanont T., Kuo Y., Tang C., Li C., Qiu Y., Lu B., et al. In vitro and in vivo CYP3A64 induction and inhibition studies in rhesus monkeys: a preclinical approach for CYP3A-mediated drug interaction studies. Drug Metab Dispos 34 (2006) 1546-1555
13. Lee A.M., Yue J., and Tyndale R.F. In vivo and in vitro characterization of chlorzoxazone metabolism and hepatic CYP2E1 levels in African Green monkeys: induction by chronic nicotine treatment. Drug Metab Dispos 34 (2006) 1508-1515
14. Joshi M., and Tyndale R.F. Regional and cellular distribution of CYP2E1 in monkey brain and its induction by chronic nicotine. Neuropharmacology 50 (2006) 568-575
15. Lee A.M., Miksys S., and Tyndale R.F. Phenobarbital increases monkey in vivo nicotine disposition and induces liver and brain CYP2B6 protein. Br J Pharmacol 148 (2006) 786-794
16. Ged C., Umbenhauer D.R., Bellew T.M., Bork R.W., Srivastava P.K., Shinriki N., et al. Characterization of cDNAs, mRNAs, and proteins related to human liver microsomal cytochrome P-450 (S)-mephenytoin 4′-hydroxylase. Biochemistry 27 (1988) 6929-6940
17. Uno Y., Fujino H., Kito G., Kamataki T., and Nagata R. CYP2C76, a novel cytochrome P450 in cynomolgus monkey, is a major CYP2C in liver, metabolizing tolbutamide and testosterone. Mol Pharmacol 70 (2006) 477-486
18. Mitsuda M., Iwasaki M., and Asahi S. Cynomolgus monkey cytochrome P450 2C43: cDNA cloning, heterologous expression, purification and characterization. J Biochem (Tokyo) 139 5 (May) (2006) 865-872
19. Tang W., Stearns R.A., Wang R.W., Chiu S.H., and Baillie T.A. Roles of human hepatic cytochrome P450s 2C9 and 3A4 in the metabolic activation of diclofenac. Chem Res Toxicol 12 (1999) 192-199
20. Tang W., Stearns R.A., Kwei G.Y., Iliff S.A., Miller R.R., Egan M.A., et al. Interaction of diclofenac and quinidine in monkeys: stimulation of diclofenac metabolism. J Pharmacol Exp Ther 291 (1999) 1068-1074
21. Weaver R.J., Dickins M., and Burke M.D. A comparison of basal and induced hepatic microsomal cytochrome P450 monooxygenase activities in the cynomolgus monkey (Macaca fascicularis) and man. Xenobiotica 29 (1999) 467-482
22. Mitsuda M., Iwasaki M., and Asahi S. Cynomolgus monkey cytochrome P450 2C43: cDNA cloning, heterologous expression, purification and characterization. J Biochem (Tokyo) 139 (2006) 865-872
23. Prueksaritanont T., Li C., Tang C., Kuo Y., Strong-Basalyga K., and Carr B. Rifampin induces the in vitro oxidative metabolism, but not the in vivo clearance of diclofenac in rhesus monkeys. Drug Metab Dispos (2006)
24. Mei Q., Tang C., Assang C., Lin Y., Slaughter D., Rodrigues A.D., et al. Role of a potent inhibitory monoclonal antibody to cytochrome P-450 3A4 in assessment of human drug metabolism. J Pharmacol Exp Ther 291 (1999) 749-759
25. Carr B.A., Norcross R., Fang Y., Lu P., Rodrigues A.D., Shou M., et al. Characterization of the rhesus monkey CYP3A64 enzyme: species comparisons of CYP3A substrate specificity and kinetics using baculovirus-expressed recombinant enzymes. Drug Metab Dispos 34 10 (2006) 1703-1712
26. Kenny J.R., Maggs J.L., Meng X., Sinnott D., Clarke S.E., Park B.K., et al. Syntheses and characterization of the acyl glucuronide and hydroxy metabolites of diclofenac. J Med Chem 47 (2004) 2816-2825
27. Chiba M., Nishime J.A., and Lin J.H. Potent and selective inactivation of human liver microsomal cytochrome P-450 isoforms by L-754,394, an investigational human immune deficiency virus protease inhibitor. J Pharmacol Exp Ther 275 (1995) 1527-1534
28. Tang C., and Ma B. Glycosidation of an endothelin ET(A) receptor antagonist and diclofenac in human liver microsomes: aglycone-dependent UDP-sugar selectivity. Drug Metab Dispos 33 (2005) 1796-1802
29. Tang C., Shou M., and Rodrigues A.D. Substrate-dependent effect of acetonitrile on human liver microsomal cytochrome P450 2C9 (CYP2C9) activity. Drug Metab Dispos 28 (2000) 567-572
30. Ngui J.S., Tang W., Stearns R.A., Shou M., Miller R.R., Zhang Y., et al. Cytochrome P450 3A4-mediated interaction of diclofenac and quinidine. Drug Metab Dispos 28 (2000) 1043-1050
31. Shen S., Marchick M.R., Davis M.R., Doss G.A., and Pohl LR. Metabolic activation ofdiclofenac by human cytochrome P450 3A4: role of 5-hydroxydiclofenac. Chem Res Toxicol 12 (1999) 214-222
32. Newton D.J., Wang R.W., and Lu A.Y. Cytochrome P450 inhibitors, evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 23 (1995) 154-158
33. Bourrie M., Meunier V., Berger Y., and Fabre G. Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J Pharmacol Exp Ther 277 (1996) 321-332
34. Mancy A., Broto P., Dijols S., Dansette P.M., and Mansuy D. The substrate binding site of human liver cytochrome P450 2C9: an approach using designed tienilic acid derivatives and molecular modeling. Biochemistry 34 (1995) 10365-10375
35. McGinnity D.F., Berry A.J., Kenny J.R., Grime K., and Riley R.J. Evaluation of time-dependent cytochrome P450 inhibition using cultured human hepatocytes. Drug Metab Dispos 34 (2006) 1291-1300
36. Bort R., Mace K., Boobis A., Gomez-Lechon M.J., Pfeifer A., and Castell J. Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. Biochem Pharmacol 58 (1999) 787-796
37. Lopez-Garcia M.P., Dansette P.M., and Mansuy D. Thiophene derivatives as new mechanism-based inhibitors of cytochromes P-450: inactivation of yeast-expressed human liver cytochrome P-450 2C9 by tienilic acid. Biochemistry 33 (1994) 166-175
38. Eagling V.A., Tjia J.F., and Back D.J. Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes. Br J Clin Pharmacol 45 (1998) 107-114
39. Bogaards J.J., Bertrand M., Jackson P., Oudshoorn M.J., Weaver R.J., van Bladeren P.J., et al. Determining the best animal model for human cytochrome P450 activities: a comparison of mouse, rat, rabbit, dog, micropig, monkey and man. Xenobiotica 30 (2000) 1131-1152
40. Kobayashi K., Urashima K., Shimada N., and Chiba K. Selectivities of human cytochrome P450 inhibitors toward rat P450 isoforms: study with cDNA-expressed systems of the rat. Drug Metab Dispos 31 (2003) 833-836
41. Li J., Liu Y., Zhang J.W., Wei H., and Yang L. Characterization of hepatic drug-metabolizing activities of Bama miniature pigs (Sus scrofa domestica): comparison with human enzyme analogs. Comp Med 56 (2006) 286-290
42. Rettie A.E., and Jones J.P. Clinical and toxicological relevance of CYP2C9: drug-drug interactions and pharmacogenetics. Annu Rev Pharmacol Toxicol 45 (2005) 477-494
43. Wang P.P., Beaune P., Kaminsky L.S., Dannan G.A., Kadlubar F.F., Larrey D., et al. Purification and characterization of six cytochrome P-450 isozymes from human liver microsomes. Biochemistry 22 (1983) 5375-5383